The U.S. peptide therapeutics CDMO market size was estimated at USD 590.00 million in 2025 and is projected to be worth around USD 1,530.31 million by 2035, expanding at a CAGR of 10% from 2026 to 2035. Growing due to cost-effective manufacturing services and rapid growth of the pharmaceutical industry in emerging countries.

U.S. Peptide Therapeutics CDMO Market Statical Scope

To increase efficiency and lower costs, pharmaceutical and biotech companies are increasingly outsourcing drug development and commercial manufacturing to specialized CDMO providers; investments in cell and gene therapy production facilities, biologics manufacturing, and high-potency drug development are also rising significantly; and the adoption of digital manufacturing technologies and automation is supporting faster and more scalable therapeutic production.

The U.S. therapeutics CDMO market is experiencing strong growth. To increase productivity and cut expenses, pharmaceutical and biotech firms are increasingly contracting with specialized CDMO suppliers to handle drug research and commercial manufacturing. Investments in biologics production, high-potency medication development, and cell and gene therapy production facilities are also rising dramatically. Additionally, faster and more scalable therapeutic production is supported by the use of automation and digital manufacturing technology.

The therapeutics CDMO market in the U.S. is driven by strong biotechnology research activities and rising demand for advanced therapy manufacturing services. Growing investments in cell and gene therapy development are increasing the need for specialized contract manufacturing support. The country is also witnessing higher adoption of automation and digital manufacturing technologies to improve production speed and scalability.

U.S. Peptide Therapeutics CDMO Market Share, By Synthesis Method, 2025 (%)

• Solid-Phase Peptide Synthesis (SPPS): Solid-phase peptide synthesis (SPPS) segment dominated the market in 2025 with a market share of 34% driven by rising investments in cutting edge peptide manufacturing technologies and a robust market for complex peptide therapeutics. The growth of the segment was further reinforced by the presence of prominent biotechnology and pharmaceutical companies.
• Liquid-Phase Peptide Synthesis (LPPS): Liquid-phase peptide synthesis (LPPS) segment was the fastest growing in the market with a share of 11% driven by the growing demand for peptide synthesis techniques that are both affordable and scalable growing use in the manufacturing of commercial peptides also helped the segment grow.

U.S. Peptide Therapeutics CDMO Market Share, By Service Type, 2025 (%)

• API development & manufacturing: API development & manufacturing segment dominated the market in 2025 with a market share of 22% driven by increasing outsourcing activities among pharmaceutical companies and rising demand for commercial scale peptide production. Strong regulatory expertise and manufacturing infrastructure further supported the segment.
• Process development & optimization: Process development & optimization segment was the fastest growing in the market with a share of 14% driven by the rising need for improving manufacturing efficiency, reducing production costs, and enhancing process scalability. Growing adoption of advanced analytical technologies also accelerated demand.

U.S. Peptide Therapeutics CDMO Market Share, By Peptide Type, 2025 (%)

• Generic peptide: Generic peptide segment was the fastest growing in the market with a share of 19% driven by increasing demand for affordable peptide therapeutics and expansion of generic drug manufacturing capabilities in emerging economies.
• Innovative/Novel Peptides: Innovative/novel peptide segment dominated the market in 2025 with a market share of 22% driven by an increase in clinical research activities and investments in peptide drug innovation. Demand was further increased by growing partnerships between research institutions and biotech firms.

U.S. Peptide Therapeutics CDMO Market Share, By Application Area, 2025 (%)

• Oncology & Cancer Treatment: Oncology & Cancer Treatment segment dominated the market in 2025 with a market share of 24%, driven by the growing development of peptide based targeted therapies and the rising incidence of cancer. Segment dominance was further enhanced by significant investment in clinical trials and oncology drug research.
• Diabetes & Metabolic Disorders: The diabetes and metabolic disorder segment was the fastest growing in the market with a share of 18% driven by the rising number of people with diabetes and the expanding use of peptide-based GLP1 treatments for the treatment of metabolic disease. Growth was also aided by growing awareness of obesity treatment.

U.S. Peptide Therapeutics CDMO Market Share, By Scale of Operation, 2025 (%)

• Research & Development Scale: The Research & Development scale segment was the fastest growing in the market, with a share of 20%, driven by expanding investments in early-stage therapeutics innovation and peptide discovery programs. Demand was further accelerated by partnerships between CDMOs and biotechnology companies.
• Clinical Trial Manufacturing: The Clinical Trial Manufacturing segment dominated the market in 2025 with a market share of 18%, driven by the growing outsourcing of trial scale manufacturing operations and the growing number of peptide therapeutics entering clinical trials . Growth in the segment was also aided by the expansion of regulatory approvals for experimental treatments.

U.S. Peptide Therapeutics CDMO Market Share, By End User Type, 2025 (%)

• Large Pharmaceutical Companies: Large pharmaceutical companies segment dominated the market in 2025 with a market share of 28% driven by rising outsourcing activities and increasing peptide drug commercialization initiatives across the region.
• Biotechnology Companies: The Biotechnology companies segment was the fastest growing in the market with a share of 24%, driven by a growing startup ecosystem, increasing R&D funding, and rising peptide therapeutic innovation activities.

Competitive Landscape

The U.S. therapeutics CDMO market is highly advanced with strong competition among global and domestic contract manufacturing organizations. Companies are heavily investing in biologics, mRNA, and cell and gene therapy manufacturing to meet increasing demand for advanced therapeutics. Technological advancements, automation, and strategic acquisitions are further enhancing competitive intensity in the market. Major companies operating in the U.S. market include Thermo Fisher Scientific, Catalent, Pfizer CentreOne, Charles River Laboratories, Curia Global, and National Resilience.

Segments Covered in the Report

By Synthesis Method

• Solid-Phase Peptide Synthesis (SPPS)
• Liquid-Phase Peptide Synthesis (LPPS)
• Hybrid/Mixed-Phase Synthesis
• Recombinant Peptide Production
• Chemical Synthesis Methods
• Enzymatic Synthesis Approaches
• Fragment Condensation Techniques
• Convergent Synthesis Strategies

By Service Type

• API Development & Manufacturing
• Process Development & Optimization
• Analytical Method Development & Validation
• Regulatory Affairs & CMC Support
• Formulation Development
• Fill-Finish & Packaging Services
• Quality Control & Assurance
• Clinical Trial Material Manufacturing
• Commercial Manufacturing
• Technology Transfer Services

By Peptide Type

• Generic Peptides
• Innovative/Novel Peptides
• Modified Peptides (PEGylated, Lipidated)
• Cyclic Peptides
• Stapled Peptides
• Peptide-Drug Conjugates (PDCs)
• Antimicrobial Peptides
• Hormonal Peptides
• Therapeutic Proteins & Peptides
• Cosmetic & Nutraceutical Peptides

By Application Area

• Oncology & Cancer Treatment
• Diabetes & Metabolic Disorders
• Cardiovascular Diseases
• Central Nervous System Disorders
• Infectious Diseases
• Autoimmune & Inflammatory Conditions
• Hormonal Therapies
• Pain Management
• Dermatology & Cosmetics
• Gastrointestinal Disorders

By Scale of Operation

• Research & Development Scale
• Clinical Trial Manufacturing
• Pilot Scale Production
• Commercial Scale Manufacturing
• Large-Scale Industrial Production
• Custom Small Batch Production

By End-User Type

• Large Pharmaceutical Companies
• Biotechnology Companies
• Academic & Research Institutions
• Government Research Organizations
• Clinical Research Organizations (CROs)
• Specialty Pharmaceutical Companies
• Generic Drug Manufacturers
• Cosmetic & Nutraceutical Companies